Key Points
-
Conventional radiotherapy has a limited role in the treatment of renal cell carcinoma (RCC), and is largely limited to the palliation of symptoms of metastatic disease
-
Evolving technology has facilitated the safe delivery of ablative doses of radiotherapy, in fewer fractions, and has been increasingly adopted in the clinical management of patients
-
Preclinical and clinical evidence demonstrates that RCC is sensitive to ablative doses of radiation (typically ≥8 Gy per fraction), with tumour control rates of approximately 90%
-
High-dose radiation seems to have an immunogenic effect in patients with RCC, and might explain the abscopal effects sometimes observed with this approach
-
Combinations of ablative radiotherapy with systemic targeted therapies or immunotherapies are promising approaches that might improve outcomes
Abstract
Conventional radiotherapy previously had a limited role in the definitive treatment of renal cell carcinoma (RCC), owing to the disappointing outcomes of several trials and the perceived radioresistance of this type of cancer. In this context, radiotherapy has been relegated largely to the palliation of symptoms in patients with metastatic disease, with variable rates of response. Following the availability of newer technologies that enable safe delivery of high-dose radiotherapy, stereotactic ablative radiotherapy (SABR) has become increasingly used in patients with RCC. Preclinical evidence demonstrates that RCC cells are sensitive to ablative doses of radiotherapy (≥8–10 Gy). Trials in the setting of intracranial and extracranial oligometastases, as well as primary RCC, have demonstrated excellent tumour control using this approach. Additionally, an awareness of the capacity of high-dose radiation to stimulate antitumour immunity has resulted in novel combinations of SABR with immunotherapies. Here we describe the historical application of conventional radiotherapy, the current biological understanding of the effects of radiation, and the clinical evidence supporting the use of ablative radiotherapy in RCC. We also explore emerging opportunities to combine systemic targeted agents or immunotherapies with radiation. Radiotherapy, although once an overlooked approach, is moving towards the forefront of RCC treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Delaney, G., Jacob, S., Featherstone, C. & Barton, M. The role of radiotherapy in cancer treatment. Cancer 104, 1129–1137 (2005).
Deschavanne, P. J. & Fertil, B. A review of human cell radiosensitivity in vitro. Int. J. Radiat. Oncol. Biol. Phys. 34, 251–266 (1996).
Onufrey, V. & Mohiuddin, M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 11, 2007–2009 (1985).
DiBiase, S. J. et al. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J. Urol. 158, 746–749 (1997).
Lo, S. S. et al. The development of stereotactic body radiotherapy in the past decade: a global perspective. Future Oncol. 11, 2721–2733 (2015).
Chang, J. Y. et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 16, 630–637 (2015).
Gunjur, A., Duong, C., Ball, D. & Siva, S. Surgical and ablative therapies for the management of adrenal 'oligometastases' — a systematic review. Cancer Treat. Rev. 40, 838–846 (2014).
Tunio, M. A., Hashmi, A. & Rafi, M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann. Oncol. 21, 1839–1845 (2010).
van der Werf-Messing, B. Proceedings: carcinoma of the kidney. Cancer 32, 1056–1061 (1973).
Juusela, H., Malmio, K., Alfthan, O. & Oravisto, K. J. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand. J. Urol. Nephrol. 11, 277–281 (1977).
Finney, R. The value of radiotherapy in the treatment of hypernephroma — a clinical trial. Br. J. Urol. 45, 258–269 (1973).
Kjaer, M. et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand. J. Urol. Nephrol. 21, 285–289 (1987).
Paly, J. J. et al. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 88, 618–623 (2014).
Halperin, E. C. & Harisiadis, L. The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 51, 614–617 (1983).
Wilson, D. et al. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin. Oncol. (R. Coll. Radiol.) 15, 400–407 (2003).
Fosså, S., Kjølseth, I. & Lund, G. Radiotherapy of metastases from renal cancer. Eur. Urol. 8, 340–342 (1981).
Seitz, W., Kärcher, K. & Binder, W. Radiotherapy of metastatic renal cell carcinoma. Sem. Surg. Oncol. 4, 100–102 (1998).
Brinkmann, O., Bruns, F., Prott, F. & Hertle, L. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). Anticancer Res. 19, 1583–1587 (1998).
Redman, B. G. et al. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma. Clin. Cancer Res. 4, 283–286 (1998).
Lee, J. et al. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 104, 1894–1900 (2005).
Huguenin, P. U., Kieser, S., Glanzmann, C., Capaul, R. & Lütolf, U. M. Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points. Int. J. Radiat. Oncol. Biol. Phys. 41, 401–405 (1998).
Brown, J. M., Carlson, D. J. & Brenner, D. J. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int. J. Radiat. Oncol. Biol. Phys. 88, 254–262 (2014).
Ishiyama, H., Blanco, A. I., Lo, S. S., Butler, E. B. & Teh, B. S. Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) for “radioresistant” renal cell carcinoma (RCC). J. Radiat. Oncol. 3, 339–346 (2014).
Tan, M. H. et al. Gene expression profiling of renal cell carcinoma. Clin. Cancer Res. 10, 6315S–6321S (2004).
Bhatt, R. S. et al. Hypoxia-inducible factor-2α: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 102, 358–363 (2008).
Moeller, B. J. et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8, 99–110 (2005).
Ning, S., Trisler, K., Wessels, B. W. & Knox, S. J. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80, 2519–2528 (1997).
Finkelstein, S. E. et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin. Dev. Immunol. 2011, 439752 (2011).
Fuks, Z. & Kolesnick, R. Engaging the vascular component of the tumor response. Cancer Cell 8, 89–91 (2005).
Darnell, J. E. STATs and gene regulation. Science 277, 1630–1635 (1997).
Hui, Z. et al. Radiosensitization by inhibiting STAT1 in renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 73, 288–295 (2009).
Zhu, H. et al. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy. Cancer Biol. Ther. 13, 401–407 (2012).
Kijima, T. et al. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. PLoS ONE 8, e64615 (2013).
Kothari, G., Foroudi, F., Gill, S., Corcoran, N. M. & Siva, S. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 54, 148–157 (2015).
Ranck, M. C. et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am. J. Clin. Oncol. 36, 589–595 (2013).
Samlowski, W. E. et al. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer 113, 2539–2548 (2008).
De Meerleer, G. et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 15, e170–e177 (2014).
Wersall, P. J. et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77, 88–95 (2005).
Siva, S., Pham, D., Gill, S., Corcoran, N. M. & Foroudi, F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 110, E737–E743 (2012).
Pham, D. et al. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int. J. Radiat. Oncol. Biol. Phys. 90, 1061–1068 (2014).
Staehler, M. et al. Single fraction radiosurgery for the treatment of renal tumors. J. Urol. 193, 771–775 (2015).
Ponsky, L. et al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother. Oncol. 117, 183–187 (2015).
Siva, S. et al. Principal analysis of a phase Ib trial of stereotactic body radiation therapy (SBRT) for primary kidney cancer. Int. J. Radiat. Oncol. Biol. Phys. 96, S96 (2016).
McBride, S., Wagner, A. & Kaplan, I. A phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 87, S84 (2013).
Nomiya, T. et al. Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience. Int. J. Radiat. Oncol. Biol. Phys. 72, 828–833 (2008).
Sun, M. R. et al. Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors. AJR Am. J. Roentgenol. 206, 544–553 (2016).
Eisenhauer, E. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
Siva, S. et al. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol. 12, 637–645 (2016).
Svedman, C. et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 47, 1578–1583 (2008).
Jackson, P. et al. Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial 99mTc-DMSA SPECT/CT. Radiat. Oncol. 9, 253 (2014).
Chang, J. H. et al. Stereotactic ablative body radiotherapy for primary renal cell carcinoma in non-surgical candidates: initial clinical experience. Clin. Oncol. (R. Coll. Radiol.) 28, e109–e114 (2016).
Siva, S. et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose–response relationship. Radiother. Oncol. 118, 540–546 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02613819 (2017).
University Hospital Medical Information Network (UMIN) Center. UMIN-CTR https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000005008 (2017).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT03108703 (2017).
Zeng, J., Baik, C., Bhatia, S., Mayr, N. & Rengan, R. Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncol. 15, e426–e434 (2014).
Straka, C. et al. Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J. Clin. Oncol. 31, e401–e403 (2013).
Weickhardt, A. J. et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer. J. Thorac. Oncol. 7, 1807–1814 (2012).
Spigel, D. R. et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J. Clin. Oncol. 28, 43–48 (2010).
Basille, D. et al. Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy. Ann. Pharmacother. 44, 383–386 (2010).
Yuasa, T. et al. Early onset recall pneumonitis during targeted therapy with sunitinib. BMC Cancer 13, 3 (2013).
Lordick, F., Geinitz, H., Theisen, J., Sendler, A. & Sarbia, M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int. J. Radiat. Oncol. Biol. Phys. 64, 1295–1298 (2006).
Peters, N. A., Richel, D. J., Verhoeff, J. J. & Stalpers, L. J. Bowel perforation after radiotherapy in a patient receiving sorafenib. J. Clin. Oncol. 26, 2405–2406 (2008).
Wong, P. et al. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J. Natl Cancer Inst. 106, dju329 (2014).
Staehler, M. et al. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int. 108, 673–678 (2011).
Miller, J. A. et al. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. J. Neurosurg. Spine 25, 766–774 (2016).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02855203 (2016).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02864615 (2016).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT00609934 (2015).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02019576 (2017).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT00672178 (2016).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT01896271 (2015).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02334709 (2017).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02599779 (2016).
Siva, S. et al. Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues. Clin. Cancer Res. 22, 4817–4826 (2016).
Siva, S., MacManus, M. P., Martin, R. F. & Martin, O. A. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 356, 82–90 (2015).
Matzinger, P. The danger model: a renewed sense of self. Science 296, 301–305 (2002).
Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2006).
Chakraborty, M. et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64, 4328–4337 (2004).
Park, H. J., Griffin, R. J., Hui, S., Levitt, S. H. & Song, C. W. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat. Res. 177, 311–327 (2012).
Reynders, K., Illidge, T., Siva, S., Chang, J. Y. & De Ruysscher, D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat. Rev. 41, 503–510 (2015).
Ribeiro Gomes, J. et al. Analysis of the abscopal effect with anti-PD1 therapy in patients with metastatic solid tumors. J. Immunother. 39, 367–372 (2016).
Park, S. S. et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol. Res. 3, 610–619 (2015).
Lopez-Beltran, A. et al. 2009 update on the classification of renal epithelial tumors in adults. Int. J. Urol. 16, 432–443 (2009).
Shuch, B. et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur. Urol. 67, 85–97 (2015).
Eminaga, O., Akbarov, I., Wille, S. & Engelmann, U. Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study. Int. Urol. Nephrol. 47, 1653–1663 (2015).
Nomiya, T. et al. Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience. Int. J. Radiat. Oncol. Biol. Phys. 87, S84 (2008).
Wang, Y. J. et al. Stereotactic gamma-ray body radiation therapy for asynchronous bilateral renal cell carcinoma. Radiol. Med. 119, 878–883 (2014).
Schoggl, A. et al. Gamma-knife radiosurgery for brain metastases of renal cell carcinoma: results in 23 patients. Acta Neurochir. (Wien) 140, 549–555 (1998).
Ippen, F. M. et al. Stereotactic radiosurgery for renal cancer brain metastasis: prognostic factors and the role of whole-brain radiation and surgical resection. J. Oncol. 2015, 636918 (2015).
Seastone, D. J. et al. Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinoma. Clin. Genitourin. Cancer 12, 111–116 (2014).
Ghia, A. J. et al. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of phase I/II trials. J. Neurosurg. Spine 24, 829–836 (2016).
Kano, H. et al. Outcome predictors of gamma knife radiosurgery for renal cell carcinoma metastases. Neurosurgery 69, 1232–1239 (2011).
Noel, G. et al. LINAC radiosurgery for brain metastasis of renal cell carcinoma. Urol. Oncol . 22, 25–31 (2004).
Leksell, L. et al. The stereotaxic method and radiosurgery of the brain. Acta. Chir. Scand. 102, 316–319 (1951)
Solberg, T. D. et al. in Stereotactic body radiation therapy (eds Lo, S.S. et al.). 9–35 (Springer, 2012)
Robson, C. J., Churchill, B. M. & Anderson, W. The results of radical nephrectomy for renal cell carcinoma. J. Urol. 101, 297–301 (1969)
Song, C. W. & Levitt, S. H. Vascular changes in Walker 256 carcinoma of rats following X irradiation. Radiology 100, 397–407 (1971)
Licht, M. R. & Novick, A. C. Nephron sparing surgery for renal cell carcinoma. J. Urol. 149, 1–7 (1993).
Blomgren, H., Lax, I., Naslund, I. & Svanstrom, R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta. Oncol. 34, 861–870 (1995)
Ning, S., Trisler, K., Wessels, B. W. & Knox, S. J. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80, 2519–2528 (1997).
Flanigan, R. C. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071–1076 (2004).
Flanigan, R. C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655–1659 (2001).
Mickisch, G. H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001).
Wang, L. T., Solberg, T. D., Medin, P. M. & Boone, R. Infrared patient positioning for stereotactic radiosurgery of extracranial tumors. Comput. Biol. Med. 31, 101–111 (2001).
Yan, H., Yin, F. F. & Kim, J. H. A phantom study on the positioning accuracy of the Novalis Body system. Med. Phys. 30, 3052–3060 (2003).
Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155–1159 (2003).
Ponsky, L. E. et al. Initial evaluation of Cyberknife technology for extracorporeal renal tissue ablation. Urology 61, 498–501 (2003).
Qian, G. et al. Stereotactic extra-cranial radiosurgery for renal cell carcinoma [abstract 1037]. Int J. Radiat. Oncol. Biol. Phys. 57, S283 (2003).
Lugade, A. A. et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174, 7516–7523 (2005).
Wersall, P. J. et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77, 88–95 (2005).
Svedman, C. et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 45, 870–875 (2006).
Guckenberger, M. et al. Intra-fractional uncertainties in cone-beam CT based image-guided radiotherapy (IGRT) of pulmonary tumors. Radiother. Oncol. 83, 57–64 (2007).
Walsh, L. et al. Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur. Urol. 50, 795–800 (2006).
Kishnan, A. U. et al. Feasibility of magnetic resonance imaging-guided liver stereotactic body radiation therapy: A comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based intensity modulated radiation therapy. Pract. Radiat. Oncol. 5, 330–337 (2015).
Hanna, N. et al. Survival analyses of metastatic renal cancer patients treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J. Clin. Oncol. 34, 3267–3275 (2016).
Amendola, B. E., Wolf, A. L., Coy, S. R., Amendola, M. & Bloch, L. Brain metastases in renal cell carcinoma: management with gamma knife radiosurgery. Cancer J. 6, 372–376 (1999).
Bates, J. E. et al. Radiotherapy for brain metastases from renal cell carcinoma in the targeted therapy era: the University of Rochester experience. Am. J. Clin. Oncol. http://dx.doi.org/10.1097/COC.0000000000000186 (2015).
Cochran, D. C. et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with gamma knife surgery. J. Neurosurg. 116, 978–983 (2012).
Fokas, E. et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery? Strahlenther. Onkol. 186, 210–217 (2010).
Goyal, L. K., Suh, J. H., Reddy, C. A. & Barnett, G. H. The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 47, 1007–1012 (2000).
Hernandez, L. et al. Gamma knife radiosurgery for renal cell carcinoma brain metastases. J. Neurosurg. 97, 489–493 (2002).
Hoshi, S. et al. Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients. Int. J. Urol. 9, 618–625 (2002).
Ikushima, H. et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 48, 1389–1393 (2000).
Janssen, S., Dahlke, M., Trang, N. T., Khoa, M. T. & Rades, D. Estimation of the six-month survival probability after radiosurgery for brain metastases from kidney cancer. Anticancer Res. 35, 4215–4217 (2015).
Kim, W. H. et al. Early significant tumor volume reduction after radiosurgery in brain metastases from renal cell carcinoma results in long-term survival. Int. J. Radiat. Oncol. Biol. Phys. 82, 1749–1755 (2012).
Majewski, W. et al. The efficacy of stereotactic radiotherapy for metastases from renal cell carcinoma. Neoplasma 63, 99–106 (2016).
Muacevic, A., Kreth, F., Mack, A., Tonn, J.-C. & Wowra, B. Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim. Invasive Neurosurg. 47, 203–208 (2004).
Nicolato, A. et al. Gamma knife efficacy and safety on renal cell carcinoma brain metastasis: 130 patients followed for at least 12 months. J. Radiosurg. SBRT S2.1, 129–130 (2013).
Payne, B. R., Prasad, D., Szeifert, G., Steiner, M. & Steiner, L. Gamma surgery for intracranial metastases from renal cell carcinoma. J. Neurosurg. 92, 760–765 (2000).
Rades, D. et al. Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. Anticancer Res. 35, 3571–3574 (2015).
Shuto, T., Matsunaga, S., Suenaga, J., Inomori, S. & Fujino, H. Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema. J. Neurooncol. 98, 169–175 (2010).
Altoos, B. et al. Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat. Oncol. 10, 218 (2015).
Amini, A. et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant? Pract. Radiat. Oncol. 5, e589–e596 (2015).
Balagamwala, E. H. et al. Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma: clinical article. J. Neurosurg. Spine 17, 556–564 (2012).
Gerszten, P. C. et al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J. Neurosurg. Spine 3, 288–295 (2005).
Hannan, R. et al. Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic Radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): Interim analysis. J. Clin. Oncol. 34, S25 532 (2016).
Jhaveri, P. M. et al. A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases. Acta Oncol. 51, 584–588 (2012).
Nguyen, Q.-N. et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 76, 1185–1192 (2010).
Teh, B. S. et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed. Imaging Interv. J. 3, e6 (2007).
Thibault, I. et al. Risk of vertebral compression fracture specific to osteolytic renal cell carcinoma spinal metastases after stereotactic body radiotherapy: a multi-institutional study. J. Radiosurg. SBRT 3, 297–305 (2015).
Tinkle, C. L., Shiao, S. L., Weinberg, V. K., Lin, A. M. & Gottschalk, A. R. Comparison of stereotactic body radiotherapy and conventional external beam radiotherapy in renal cell carcinoma.[abstract] J. Clin. Oncol. 33, 434 (2015).
Wang, C. J. et al. The effect of stereotactic ablative radiotherapy on time to change of systemic therapy in extra-cranial renal cell carcinoma metastases [abstract]. J. Clin. Oncol. 34, 533 (2016).
Wersäll, P. J. et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77, 88–95 (2004).
Zelefsky, M. J. et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 82, 1744–1748 (2012).
Gilson, B., Lederman, G., Qian, G., Fastaia, M. & Cangiane, L. Hypo-fractionated stereotactic extra-cranial radiosurgery (HFSR) for primary and metastatic renal cell carcinoma [abstract 2249]. Int J. Radiat. Oncol. Biol. Phys. 66, S349 (2006).
Lo, C. H., Huang, W. Y., Chao, H. L., Lin, K. T. & Jen, Y. M. Novel application of stereotactic ablative radiotherapy using CyberKnife for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: Initial clinical experiences. Oncol. Lett. 8, 355–360 (2014).
McBride, S. M., Wagner, A. A. & Kaplan, I. D. A. Phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 87, S84 (2013).
Nair, V. J. et al. Cyberknife for inoperable renal tumours: Canadian pioneering experience. Can. J. Urol. 20, 6944–6949 (2013).
Author information
Authors and Affiliations
Contributions
All authors contributed equally to all aspects of the preparation of this manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- SABR
-
Stereotactic ablative radiotherapy, refers to high-dose per fraction, conformal radiotherapy, typically delivered in one or a few sessions.
- Gy
-
Gray, the unit of radiation, used in the International System of Units, defined in joules per kilogram.
- α-subunit of hypoxia inducible factor
-
(HIF-1α). A subunit of the transcription factor hypoxia inducible factor-1, which has a critical role in the management of the cellular response to hypoxia, and can stimulate transcription of a number of genes that are responsible for various functions, including angiogenesis, cell proliferation and survival.
- von Hippel Lindau (VHL) tumour suppressor gene
-
A regulator of tumorigenesis located on chromosome 3, which is subject to dominant inheritance and associated with cancer growth when lost or mutated.
- E3 ubiquitin ligase
-
A protein that is involved in the regulation of cell trafficking, DNA repair, and signalling, as well as cell-cycle control.
- Gap 2 (G2) phase
-
G2 phase is a phase of the cell cycle that directly precedes mitosis, during which the cell undergoes rapid growth and protein synthesis. The checkpoint between G2 and mitosis results in cell-cycle arrest during the G2 phase in response to stressors such as oxidative stress or radiation.
- α/β ratio
-
A measure of a tissue or tumour response to a specific radiation dose.
- Caki-1
-
A human clear cell RCC cell line derived from a patient of white ethnicity. This cell line has an epithelial morphology and provides a useful model for the study of kidney cancer.
- A498
-
A commonly used renal cell carcinoma cell line typically used to model the behaviour of clear cell RCC.
- SMPD1
-
Sphingomyelin phosphodiesterase 1, an enzyme that is found in lysosomes and has a role in the conversion of sphingomyelin to ceramide, and in maintaining the normal structure and function of the cell.
- SRS
-
Stereotactic radiosurgery, describes a high, single-fraction, ablative dose of radiotherapy, delivered in a very conformal, precise manner.
- SBRT
-
Stereotactic body radiotherapy, high dose-per-fraction ablative and highly conformal radiotherapy typically delivered as a single, or small number of fractions to an extracranial site. Often used interchangeably with SABR.
- CKD
-
Chronic kidney disease, usually a progressive irreversible decline in kidney function, typically over a period of months to years
- High mobility group protein B1
-
A chromatin protein that is secreted by immune cells and acts as a mediator of inflammation
Rights and permissions
About this article
Cite this article
Siva, S., Kothari, G., Muacevic, A. et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol 14, 549–563 (2017). https://doi.org/10.1038/nrurol.2017.87
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.87
This article is cited by
-
A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma
World Journal of Urology (2024)
-
Stereotaktische Strahlentherapie von primären Nierenzellkarzinomen
InFo Hämatologie + Onkologie (2023)
-
SBRT von primären Nierenzellkarzinomen – Langzeitergebnisse der IROCK-Datenbank
Strahlentherapie und Onkologie (2023)
-
Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma — buying time or time to change?
Nature Reviews Urology (2022)
-
The Value of Metastasectomy in Renal Cell Carcinoma in 2021
Indian Journal of Surgery (2022)